Skip to content
Peptigraph home

Tirzepatide for Bone Health: What the Evidence Shows

What human and animal studies show about Tirzepatide for bone health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human observational
Human studies
15
PubMed records, our ledger
Animal studies
0
PubMed records, our ledger
Studies we summarised
1
with an outcome for bone health

Evidence for bone health

Each row is an outcome related to bone health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide for bone health: outcomes in published studies
OutcomeResultStudy typeSource
Osteoporosis or fragility fractureTirzepatide was associated with a higher risk of osteoporosis or fragility fracture than other GLP-1 RAs (hazard ratio 1.44, 95% CI 1.22-1.69); observational, association only.Human observationaln = 459886Diabetes research and clinical practice 2025, PMID 41218687

PubMed records for Tirzepatide and bone health: 15 human, 0 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human observational evidence, 3 of 4Diabetes research and clinical practice 2025, PMID 41218687

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Bone density and what was actually studied

MedlinePlus defines bone density as the amount of calcium and other minerals in bone.[2]

MedlinePlus defines osteoporosis as a disease in which bones become weak and are likely to fracture.[3]

A large real-world health-record cohort found that starting tirzepatide was associated with a higher risk of osteoporosis or fragility fracture than starting other GLP-1 drugs.[1]

Against other GLP-1 drugs the hazard ratio for the main outcome was 1.44, and 1.61 for starting osteoporosis therapy.[1]

Reading that result carefully

Against people not on any GLP-1 drug, the hazard ratio for tirzepatide users was 1.48. The hazard ratio for other GLP-1 drugs was 1.07.[1]

The primary outcome was new-onset osteoporosis or fragility fracture within a 14-month follow-up. It is an observational cohort, so it cannot show that tirzepatide caused the fractures.[1]

In the SURMOUNT-1 DXA substudy, about 75% of the weight lost was fat mass and 25% lean mass, for both tirzepatide and placebo.[4]

Other peptides people research for bone health

Common questions

Does Tirzepatide help with bone health?

The strongest study we summarise for bone health is human observational evidence, across 1 study with an outcome for bone health. That is not proof it works in people.

Is Tirzepatide approved for bone health?

Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.

Does Mounjaro (tirzepatide) affect bone density?

No study cited here measured bone density directly. One cohort linked tirzepatide to more osteoporosis or fragility fracture diagnoses than other GLP-1 drugs, with a hazard ratio of 1.44.[1]

Can tirzepatide help osteoporosis?

No study cited here shows that it does. The one cohort on tirzepatide and osteoporosis found a higher risk of osteoporosis or fragility fracture compared with other GLP-1 drugs.[1]

More on Tirzepatide

Sources

  1. 1Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.Diabetes research and clinical practice · 2025PMID 41218687Accessed 2 Oct 2026
  2. 2medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  3. 3Official web pageOfficial web page · web page
  4. 4Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026

Found an error? Report a correction.